Abstract：
Drug-induced fatty liver disease (DIFLD) is a basic clinicopathological example of drug-induced liver injury (DILI). Some drugs can inhibit β-oxidation in hepatocyte mitochondria, leading to steatosis in the liver. Additionally, drug-induced inhibition of β-oxidation and the electron transport chain (ETC) can lead to increased production of reactive oxygen species (ROS) such as peroxynitrite (ONOO-). Therefore, it is reasonable to suspect that compared to a healthy liver, viscosity and ONOO- levels are elevated in livers during DIFLD. A novel, smart, dual-response fluorescent probe-Mito-VO-was designed and synthesized for the simultaneous detection of viscosity and ONOO- content. This probe had a large emission shift of 293 nm and was capable of monitoring the viscosity of, and the ONOO- content in, cell and animal models alike, either individually or simultaneously. For the first time, Mito-VO was successfully used to demonstrate the elevated viscosity and the amount of ONOO- in livers from mice with DIFLD.
摘要：
药物性脂肪肝(DIFLD)是药物性肝损伤(DILI)的一个基本临床病理实例。一些药物可以抑制肝细胞线粒体的β-氧化，导致肝脏脂肪变性.此外,药物诱导的β-氧化和电子传递链（ETC）的抑制可导致活性氧（ROS）如过氧亚硝酸盐（ONOO-）的产生增加。因此,有理由怀疑，与健康的肝脏相比，在DIFLD期间，肝脏中的粘度和ONOO-水平升高。一部小说,聪明,设计并合成了双响应荧光探针Mito-VO-，用于同时检测粘度和ONOO-含量。该探针具有293nm的大发射位移，能够监测粘度，和ONOO-含量，细胞和动物模型一样，单独或同时。第一次,Mito-VO成功地用于证明来自具有DIFLD的小鼠的肝脏中的升高的粘度和ONOO-的量。
